Synergy Pharmaceuticals - Aus dem Windschatten an die Spitze - 500 Beiträge pro Seite
eröffnet am 09.07.12 20:52:50 von
neuester Beitrag 24.08.12 12:41:35 von
neuester Beitrag 24.08.12 12:41:35 von
Beiträge: 6
ID: 1.175.426
ID: 1.175.426
Aufrufe heute: 0
Gesamt: 694
Gesamt: 694
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 5962 | |
| vor 1 Stunde | 4840 | |
| vor 1 Stunde | 4038 | |
| heute 15:47 | 3548 | |
| vor 1 Stunde | 2481 | |
| heute 14:53 | 1937 | |
| heute 15:18 | 1860 | |
| heute 13:07 | 1451 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.178,49 | +1,39 | 224 | |||
| 2. | 2. | 1,1100 | -19,57 | 124 | |||
| 3. | 3. | 0,1905 | +0,79 | 105 | |||
| 4. | 5. | 9,3650 | +1,30 | 64 | |||
| 5. | 4. | 171,36 | +0,69 | 55 | |||
| 6. | Neu! | 11,905 | +14,97 | 39 | |||
| 7. | Neu! | 0,4250 | -1,16 | 38 | |||
| 8. | Neu! | 4,7650 | +6,24 | 35 |
Feedback
Dieser Wert hat unbedingt seinen eigenen Thread verdient: Synergy Pharmaceuticals
Eine kurze Vorstellung aus einer Empfehlung:
Synergy Pharmaceuticals-Aktie: Kursgewinne von 100% und mehr sind möglich
Endingen (www.aktiencheck.de) - Die Experten von "Hot Stocks Investor" empfehlen Anlegern mit der Übergewichtung der Biotech-Branche weiter konsequent fortzufahren und das Portfolio unter anderem mit der Aktie von Synergy Pharmaceuticals (ISIN US8716393082/ WKN A1JQT3) weiter auszubauen.
Die Gesellschaft lege ihr Hauptaugenmerk auf die Entwicklung von neuen Therapieformen von Magen-/Darmerkrankungen. Mit Plecanatide habe man bereits ein Präparat in der Pipeline, welches die Phase IIa der klinischen Forschungsreihen erfolgreich abgeschlossen habe und sich derzeit in der Phase II/III befinde. Bei SP-333 sei man hingegen in einem noch deutlich früheren, vorklinischen Stadium.
Die Analysten von Summer Street Research, Brean Murray, Roth Capital sowie von RF Lafferty würden sich vom Potenzial überzeugt zeigen und den Break-Even für 2015 prognostizieren. Die Analysten von Brean Murray würden bereits für 2016 mit einem EpS von mehr als 2 USD rechnen, womit das KGV bei knapp 3 läge. Die Kursziele der Analystenhäuser befänden sich in einer Bandbreite von 9 bis 13 USD.
Die Experten wären bei anhaltend positiven Studienergebnissen jedoch auch von einer Komplettübernahme durch einen finanzkräftigen Biotech/ Pharma-Konzern in den nächsten sechs bis 18 Monaten nicht überrascht.
Die Experten von "Hot Stocks Investor" halten bei der Synergy Pharmaceuticals-Aktie in den kommenden zwölf Monaten Kursgewinne von 100% und mehr für möglich.
http://www.onvista.de/analysen/empfehlungen/artikel/08.05.20…
Das Unternehmen wird an der Börse mit knapp 300 Mio Dollar bewertet. Der direkte Konkurrent
Ironwood hat es zu einer Marktkapitalisierung in Höhe von 1,5 Mrd Dollar gebracht. Deren
Produkt ist Plecanatide ein knappes Jahr in der Entwicklung voraus. Aber die bisherigen Studien
zeigen, dass das Sicherheits-/Verträglichkeitsprofil von Plecanatide vorteilhafter ist.
Um die Bewertungsdivergenzen vollständig zu machen sei angemerkt, dass Ironwood nur
zu 50% an den Umsätzen ihres Produktes partizipieren wird. IRWD hat geschafft, was
Synergy noch bevor steht - sie haben einen Partner für die Vermarktung des Produkt-
kandidaten gefunden. Zudem entscheidet die FDA im September bereits über die Zulassung des
Ironwood-Produkts. In deren Fahrwasser sollte Synergy bereits Kurssteigerungen erfahren können.
Danach stehen im 4. Quartal die eigenen zulassungsrelevanten Ergebnisse zu Plecanatide
an.
Da die Rechte an Plecanatide zu 100% bei Synergy liegen, ist ein Bewertungsabschlag zu
Ironwood schwer nachvollziehbar. Synergy wird mit positiven Phase III - Daten sicherlich
einen Großteil des Bewertungsabschlags aufholen können. Ich sehe bis zur Verkündung
der Ergebnisse zweistellige Kurse bei Synergy. Der heutige Kurs steht bei $ 4,64...
Eine kurze Vorstellung aus einer Empfehlung:
Synergy Pharmaceuticals-Aktie: Kursgewinne von 100% und mehr sind möglich
Endingen (www.aktiencheck.de) - Die Experten von "Hot Stocks Investor" empfehlen Anlegern mit der Übergewichtung der Biotech-Branche weiter konsequent fortzufahren und das Portfolio unter anderem mit der Aktie von Synergy Pharmaceuticals (ISIN US8716393082/ WKN A1JQT3) weiter auszubauen.
Die Gesellschaft lege ihr Hauptaugenmerk auf die Entwicklung von neuen Therapieformen von Magen-/Darmerkrankungen. Mit Plecanatide habe man bereits ein Präparat in der Pipeline, welches die Phase IIa der klinischen Forschungsreihen erfolgreich abgeschlossen habe und sich derzeit in der Phase II/III befinde. Bei SP-333 sei man hingegen in einem noch deutlich früheren, vorklinischen Stadium.
Die Analysten von Summer Street Research, Brean Murray, Roth Capital sowie von RF Lafferty würden sich vom Potenzial überzeugt zeigen und den Break-Even für 2015 prognostizieren. Die Analysten von Brean Murray würden bereits für 2016 mit einem EpS von mehr als 2 USD rechnen, womit das KGV bei knapp 3 läge. Die Kursziele der Analystenhäuser befänden sich in einer Bandbreite von 9 bis 13 USD.
Die Experten wären bei anhaltend positiven Studienergebnissen jedoch auch von einer Komplettübernahme durch einen finanzkräftigen Biotech/ Pharma-Konzern in den nächsten sechs bis 18 Monaten nicht überrascht.
Die Experten von "Hot Stocks Investor" halten bei der Synergy Pharmaceuticals-Aktie in den kommenden zwölf Monaten Kursgewinne von 100% und mehr für möglich.
http://www.onvista.de/analysen/empfehlungen/artikel/08.05.20…
Das Unternehmen wird an der Börse mit knapp 300 Mio Dollar bewertet. Der direkte Konkurrent
Ironwood hat es zu einer Marktkapitalisierung in Höhe von 1,5 Mrd Dollar gebracht. Deren
Produkt ist Plecanatide ein knappes Jahr in der Entwicklung voraus. Aber die bisherigen Studien
zeigen, dass das Sicherheits-/Verträglichkeitsprofil von Plecanatide vorteilhafter ist.
Um die Bewertungsdivergenzen vollständig zu machen sei angemerkt, dass Ironwood nur
zu 50% an den Umsätzen ihres Produktes partizipieren wird. IRWD hat geschafft, was
Synergy noch bevor steht - sie haben einen Partner für die Vermarktung des Produkt-
kandidaten gefunden. Zudem entscheidet die FDA im September bereits über die Zulassung des
Ironwood-Produkts. In deren Fahrwasser sollte Synergy bereits Kurssteigerungen erfahren können.
Danach stehen im 4. Quartal die eigenen zulassungsrelevanten Ergebnisse zu Plecanatide
an.
Da die Rechte an Plecanatide zu 100% bei Synergy liegen, ist ein Bewertungsabschlag zu
Ironwood schwer nachvollziehbar. Synergy wird mit positiven Phase III - Daten sicherlich
einen Großteil des Bewertungsabschlags aufholen können. Ich sehe bis zur Verkündung
der Ergebnisse zweistellige Kurse bei Synergy. Der heutige Kurs steht bei $ 4,64...
Synergy Pharmaceuticals Signs Definitive Agreement to Acquire Callisto Pharmaceuticals
NEW YORK, July 20, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (SGYP) and Callisto Pharmaceuticals, Inc. (CLSP) announced today that they have entered into a definitive merger agreement pursuant to which Callisto will merge into Synergy.
Under the terms of the merger agreement, each outstanding share of Callisto common stock will be exchanged for 0.17 shares of Synergy common stock and the 22,295,000 shares of Synergy held by Callisto will be canceled. In addition, the shares of common stock of Synergy issued to the Callisto stockholders will be subject to a lockup beginning on the effective date of the merger and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the merger agreement). Under the terms of the merger agreement, at closing, Synergy will issue, and Callisto stockholders will receive, in a tax-free exchange, shares of Synergy common stock such that Callisto stockholders will own approximately 38.3 percent of the combined company on a pro forma basis and Synergy stockholders will own approximately 61.7 percent. Completion of the transaction is subject to the approval of Synergy and Callisto shareholders, required regulatory approvals and certain other conditions as set forth in the definitive merger agreement. The transaction is expected to close by the end of October 2012.
Canaccord Genuity Inc. is acting as exclusive financial advisor to Synergy and Brean Murray, Carret & Co. is acting as exclusive financial advisor to Callisto.
http://finance.yahoo.com/news/synergy-pharmaceuticals-signs-…
NEW YORK, July 20, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (SGYP) and Callisto Pharmaceuticals, Inc. (CLSP) announced today that they have entered into a definitive merger agreement pursuant to which Callisto will merge into Synergy.
Under the terms of the merger agreement, each outstanding share of Callisto common stock will be exchanged for 0.17 shares of Synergy common stock and the 22,295,000 shares of Synergy held by Callisto will be canceled. In addition, the shares of common stock of Synergy issued to the Callisto stockholders will be subject to a lockup beginning on the effective date of the merger and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the merger agreement). Under the terms of the merger agreement, at closing, Synergy will issue, and Callisto stockholders will receive, in a tax-free exchange, shares of Synergy common stock such that Callisto stockholders will own approximately 38.3 percent of the combined company on a pro forma basis and Synergy stockholders will own approximately 61.7 percent. Completion of the transaction is subject to the approval of Synergy and Callisto shareholders, required regulatory approvals and certain other conditions as set forth in the definitive merger agreement. The transaction is expected to close by the end of October 2012.
Canaccord Genuity Inc. is acting as exclusive financial advisor to Synergy and Brean Murray, Carret & Co. is acting as exclusive financial advisor to Callisto.
http://finance.yahoo.com/news/synergy-pharmaceuticals-signs-…
Synergy Pharmaceuticals Strengthened By Merger Agreement
Synergy Pharmaceuticals (SGYP), a company with major catalysts pending and a potential billion dollar product in the pipeline, and Callisto Pharmaceuticals (CLSP.OB) announced on Friday that the two companies have entered into a definitive merger agreement. Callisto had previously held over twenty two million shares of SGYP stock and under the terms of the agreement those shares will be cancelled and Callisto shareholders, in turn, will be granted 0.17 shares of Synergy common stock for each outstanding share of Callisto common stock.
Another key takeaway from Friday's announcement is that the Synergy shares issued to Callisto shareholders would be "locked up" for eighteen months following the completion of the deal, barring a "Change of Control" event, as noted in the press release.
These are key points to remember and the agreement should be viewed as an encouraging turn of events for Synergy shareholders, in my opinion.
Previous to this merger agreement, Callisto had already owned roughly forty percent of Synergy stock. Many large funds and institutions are hesitant to buy into a company when only one entity - in this case Callisto - already owns such a significant portion of that company. The fact that those Synergy shares owned by Callisto will now be cancelled and then reissued and spread evenly throughout the Callisto shareholder base alleviates that hurdle. Once the deal is consummated, the door is open for funds and institutions to start buying in again, which significantly enhances the prospects of growth for shareholders over the short, mid and long terms.
There were quite a few investors out there questioning why there was not more institutional interest in Synergy if the prospects for Plecanatide, currently being developed for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C), were so bright. This merger agreement looks to be a move to answer those concerns.
As outlined on previous occasions, data from a key II/III Plecanatide trial are due to be released later this year. It is widely expected that the results from this trial will be positive, based on previous studies of both Plecanatide and also Linaclotide, a product being developed by Ironwood Pharmaceuticals' (IRWD) that shares origins and the same mechanism of action with Plecanatide.
With that being said, Synergy may hold a distinct advantage with Plecanatide over Ironwood's Linaclotide that positions the company to achieve quick market share, should it make it to market.
During Ironwood's Linaclotide trials, the treatment was successful in alleviating constipation when compared to a placebo, but the kicker is that side effects included cases of extreme diarrhea. Some cases were extreme enough to force 6% of the patients to abandon the trial altogether. No such side effects were noted during Plecanatide trials, according to publicly-released information.
That's a huge benefit for team Synergy.
Ironwood does hold the advantage, however, of potentially making it to market with its product first. The FDA is slated to announce its approval decision for Linaclotide later this year, well before it would be expected that Plecanatide hit market, although that date was already pushed back once. SGYP shares rallied significantly earlier this year when it became known that the FDA decision would be pushed back by three months, giving Synergy an opportunity to play 'catch up.'
Another such delay would again benefit Synergy, but an approval would also play well for both companies, since it would validate the technology that forms the basis of both products. At that point, Linaclotide would be the first to eat up market share, but Plecanatide could quickly negate those gains, when/if it hits market, on the merit of its superior side effect profile.
Synergy, unlike Ironwood who has already signed Forest Laboratories, Inc. (FRX) as a partner and will therefore have to split revenue, is still yet to sign a partner for Plecanatide. That point brings us back to the merger agreement.
As noted in Friday's announcement, the only exception to the eighteen month lockout period for those shares of Synergy that will be issued to Callisto shareholders would be a "Change in Control" event. Although the final language of the deal is still not completed, that could read as "major partnership or buyout," both scenarios that would likely benefit SGYP shareholders. Additionally, given the encouraging prospects for the trial data to be released later this year, it's likely that shares would have experienced a runup into those results, with a further run should they turn out positive. These days in the biotech sector, many of the real moves are materializing after the announcement of late stage results, and not necessarily after an FDA approval decision.
Given the multi-billion dollar scope of the target markets for Plecanatide and the similarities between the two products, there is reason to believe that SGYP will soon look to match valuation with that of the Ironwood market cap, which currently stands at nearly a billion and a half. With institutions now free to buy in without worrying about one entity already controlling nearly half of the company, as was previously the case before the merger was announced, an increased potential for SGYP to move exists.
With large pharmaceutical companies looking for new billion dollar products, chances are that Synergy is going to be looked at, especially if results are positive later this year. Pfizer (PFE) is already one company on the prowl, while GlaxoSmithKline (GSK) has also made news in the merger and acquisition space recently with the pickup of Human Genome Sciences (HGSI). Another scenario would have Synergy potentially licensing or outright selling Plecanatide, an expected big money maker, which would free resources to develop Callisto's pipeline of products that would then belong to the merged company.
Eyes will be on an all-out takeover, though, especially with the "Change of Control" language in the merger agreement and eighteen month lockup period.
Three analysts have recently issued enthusiastic 'Buy' ratings on Synergy, with each posting price targets of well more than double that of where SGYP trades today. Summer Street initiated coverage with a price target of $9, Brean Murray's rating was accompanied by a price tag of $13, and just a couple of weeks ago Roth Capital threw its own prediction into the mix with a target of $12.
The time may be now for SGYP to start matching those estimates.
http://seekingalpha.com/article/740261-synergy-pharmaceutica…
Synergy Pharmaceuticals (SGYP), a company with major catalysts pending and a potential billion dollar product in the pipeline, and Callisto Pharmaceuticals (CLSP.OB) announced on Friday that the two companies have entered into a definitive merger agreement. Callisto had previously held over twenty two million shares of SGYP stock and under the terms of the agreement those shares will be cancelled and Callisto shareholders, in turn, will be granted 0.17 shares of Synergy common stock for each outstanding share of Callisto common stock.
Another key takeaway from Friday's announcement is that the Synergy shares issued to Callisto shareholders would be "locked up" for eighteen months following the completion of the deal, barring a "Change of Control" event, as noted in the press release.
These are key points to remember and the agreement should be viewed as an encouraging turn of events for Synergy shareholders, in my opinion.
Previous to this merger agreement, Callisto had already owned roughly forty percent of Synergy stock. Many large funds and institutions are hesitant to buy into a company when only one entity - in this case Callisto - already owns such a significant portion of that company. The fact that those Synergy shares owned by Callisto will now be cancelled and then reissued and spread evenly throughout the Callisto shareholder base alleviates that hurdle. Once the deal is consummated, the door is open for funds and institutions to start buying in again, which significantly enhances the prospects of growth for shareholders over the short, mid and long terms.
There were quite a few investors out there questioning why there was not more institutional interest in Synergy if the prospects for Plecanatide, currently being developed for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C), were so bright. This merger agreement looks to be a move to answer those concerns.
As outlined on previous occasions, data from a key II/III Plecanatide trial are due to be released later this year. It is widely expected that the results from this trial will be positive, based on previous studies of both Plecanatide and also Linaclotide, a product being developed by Ironwood Pharmaceuticals' (IRWD) that shares origins and the same mechanism of action with Plecanatide.
With that being said, Synergy may hold a distinct advantage with Plecanatide over Ironwood's Linaclotide that positions the company to achieve quick market share, should it make it to market.
During Ironwood's Linaclotide trials, the treatment was successful in alleviating constipation when compared to a placebo, but the kicker is that side effects included cases of extreme diarrhea. Some cases were extreme enough to force 6% of the patients to abandon the trial altogether. No such side effects were noted during Plecanatide trials, according to publicly-released information.
That's a huge benefit for team Synergy.
Ironwood does hold the advantage, however, of potentially making it to market with its product first. The FDA is slated to announce its approval decision for Linaclotide later this year, well before it would be expected that Plecanatide hit market, although that date was already pushed back once. SGYP shares rallied significantly earlier this year when it became known that the FDA decision would be pushed back by three months, giving Synergy an opportunity to play 'catch up.'
Another such delay would again benefit Synergy, but an approval would also play well for both companies, since it would validate the technology that forms the basis of both products. At that point, Linaclotide would be the first to eat up market share, but Plecanatide could quickly negate those gains, when/if it hits market, on the merit of its superior side effect profile.
Synergy, unlike Ironwood who has already signed Forest Laboratories, Inc. (FRX) as a partner and will therefore have to split revenue, is still yet to sign a partner for Plecanatide. That point brings us back to the merger agreement.
As noted in Friday's announcement, the only exception to the eighteen month lockout period for those shares of Synergy that will be issued to Callisto shareholders would be a "Change in Control" event. Although the final language of the deal is still not completed, that could read as "major partnership or buyout," both scenarios that would likely benefit SGYP shareholders. Additionally, given the encouraging prospects for the trial data to be released later this year, it's likely that shares would have experienced a runup into those results, with a further run should they turn out positive. These days in the biotech sector, many of the real moves are materializing after the announcement of late stage results, and not necessarily after an FDA approval decision.
Given the multi-billion dollar scope of the target markets for Plecanatide and the similarities between the two products, there is reason to believe that SGYP will soon look to match valuation with that of the Ironwood market cap, which currently stands at nearly a billion and a half. With institutions now free to buy in without worrying about one entity already controlling nearly half of the company, as was previously the case before the merger was announced, an increased potential for SGYP to move exists.
With large pharmaceutical companies looking for new billion dollar products, chances are that Synergy is going to be looked at, especially if results are positive later this year. Pfizer (PFE) is already one company on the prowl, while GlaxoSmithKline (GSK) has also made news in the merger and acquisition space recently with the pickup of Human Genome Sciences (HGSI). Another scenario would have Synergy potentially licensing or outright selling Plecanatide, an expected big money maker, which would free resources to develop Callisto's pipeline of products that would then belong to the merged company.
Eyes will be on an all-out takeover, though, especially with the "Change of Control" language in the merger agreement and eighteen month lockup period.
Three analysts have recently issued enthusiastic 'Buy' ratings on Synergy, with each posting price targets of well more than double that of where SGYP trades today. Summer Street initiated coverage with a price target of $9, Brean Murray's rating was accompanied by a price tag of $13, and just a couple of weeks ago Roth Capital threw its own prediction into the mix with a target of $12.
The time may be now for SGYP to start matching those estimates.
http://seekingalpha.com/article/740261-synergy-pharmaceutica…
Synergy Pharmaceuticals, Inc. Completes Screening and Planned Enrollment in Phase IIb/III Study in Chronic Idiopathic Constipation Patients
http://finance.yahoo.com/news/synergy-pharmaceuticals-inc-co…
http://finance.yahoo.com/news/synergy-pharmaceuticals-inc-co…
Trading Spotlight
Ausbau der Pipeline:
Synergy Pharmaceuticals Acquires FV-100 Shingles Drug From Bristol-Myers Squibb Company
NEW YORK, Aug. 23, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has signed an Asset Purchase Agreement with Bristol-Myers Squibb Company (BMY) and has acquired the assets related to FV-100, an orally available nucleoside analogue, currently being developed for the treatment of shingles, a severe, painful skin rash caused by reactivation of the varicella zoster virus -- the virus that causes chickenpox.
"FV-100 is a drug candidate we believe has great potential to treat patients suffering from shingles," said Dr. Gary S. Jacob, CEO of Synergy Pharmaceuticals. "We believe that with our expanding clinical experience in utilizing patient-reported outcome tools from our GI program, a feature that will be necessary for supporting pain-related indications for FV-100, we are in a unique position to further develop FV-100 for patients not adequately treated with present-day therapy."
FV-100 earlier completed a Phase 2a clinical trial in shingles patients, in which the drug was given to a total of 230 patients comprised of two cohorts of 115 patients dosed at 200 mg and 400 mg, respectively, and found to be well tolerated at both doses. Clinically meaningful reductions in time to resolution of clinically significant pain and in incidence of post-herpetic neuralgia were noted.
http://finance.yahoo.com/news/synergy-pharmaceuticals-acquir…
Synergy Pharmaceuticals Acquires FV-100 Shingles Drug From Bristol-Myers Squibb Company
NEW YORK, Aug. 23, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has signed an Asset Purchase Agreement with Bristol-Myers Squibb Company (BMY) and has acquired the assets related to FV-100, an orally available nucleoside analogue, currently being developed for the treatment of shingles, a severe, painful skin rash caused by reactivation of the varicella zoster virus -- the virus that causes chickenpox.
"FV-100 is a drug candidate we believe has great potential to treat patients suffering from shingles," said Dr. Gary S. Jacob, CEO of Synergy Pharmaceuticals. "We believe that with our expanding clinical experience in utilizing patient-reported outcome tools from our GI program, a feature that will be necessary for supporting pain-related indications for FV-100, we are in a unique position to further develop FV-100 for patients not adequately treated with present-day therapy."
FV-100 earlier completed a Phase 2a clinical trial in shingles patients, in which the drug was given to a total of 230 patients comprised of two cohorts of 115 patients dosed at 200 mg and 400 mg, respectively, and found to be well tolerated at both doses. Clinically meaningful reductions in time to resolution of clinically significant pain and in incidence of post-herpetic neuralgia were noted.
http://finance.yahoo.com/news/synergy-pharmaceuticals-acquir…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 226 | ||
| 126 | ||
| 105 | ||
| 68 | ||
| 56 | ||
| 39 | ||
| 38 | ||
| 35 | ||
| 32 | ||
| 27 |
| Wertpapier | Beiträge | |
|---|---|---|
| 26 | ||
| 21 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 16 |
